论文部分内容阅读
以本研究室建立的恶性胶质瘤细胞系SHG-44为抗原,通过杂交瘤技术建立了两株恒定地分泌抗胶质瘤单克隆抗体的杂交瘤细胞株SZ-38、SZ-39。以该两株单克隆抗体为生物探针,在分子生物学水平研究了两种新的胶质瘤抗原,它们分别为胶质瘤细胞表面分子量47 000及180 000的糖蛋白。通过SZ-39对脑瘤内的放射免疫定位研究,确认了该单克隆抗体应用于临床肿瘤定位诊断和导向治疗的可能性。
Based on the malignant glioma cell line SHG-44 established in this laboratory as an antigen, two hybridoma cell lines SZ-38 and SZ-39 that constantly secrete anti-glioma monoclonal antibodies were established by hybridoma technology. Using the two monoclonal antibodies as biological probes, two novel glioma antigens were studied at the molecular biology level. They were glycoproteins with a molecular weight of 47 000 and 180 000 on the surface of glioma cells. The radioimmunolocalization study of brain tumors by SZ-39 confirmed the possibility of applying this monoclonal antibody to clinical tumor localization diagnosis and targeted therapy.